Navigation Links
Determining risk for pancreatic cancer
Date:2/24/2009

In the latest clinical trial for a technique to detect pancreatic cancer, researchers found they could differentiate cells that are cancerous from those that are benign, pre-cancerous, or even early stage indicators called mucinous cystic lesions.

Pancreatic cancer is dangerous to screen for, yet deadly if ignored. The pancreas is extremely sensitive--biopsies can lead to potentially fatal complications--but with few symptoms, the cancer is usually detected too late.

The disease is the fourth largest cause of cancer-related deaths in the United States, with a five-year survival rate of less than 5 percent. If doctors can find ways to identify early precursor lesions, the disease can be prevented in most individuals.

Reporting online Feb. 10, 2009, in the journal Disease Markers, researchers from Northwestern University and Evanston Northwestern Healthcare report convincing results with their minimally invasive methods for detecting pancreatic cancer.

"This technique allows us to detect changes in cells that look normal using microscopy," says co-author Vadim Backman of Northwestern University. "This level of detail allows us to detect cancer in its earliest stages."

Their techniques, called four-dimensional elastic light scattering fingerprinting (4D-ELF) and low-coherence enhanced backscattering spectroscopy (LEBS), identify the cancer and its precursors by analyzing light reflected off cells in the duodenum, a section of the small intestine adjacent to the pancreas.

"I'm excited about this work," said Leon Esterowitz, the National Science Foundation (NSF) biophotonics program director who helped fund this study and the development of the 4D-ELF and LEBS technologies. "I believe these results are very promising, and the techniques have a high probability of success for not just detecting early pancreatic cancer, but pre-cancer, so doctors can go ahead and treat the patient while there's still a chance to defeat the disease." Esterowitz added. "For pancreatic cancer, this could lead to not only an excellent prognosis, but perhaps even a cure."

While earlier success had shown that the techniques could tell cancerous from non-cancerous tissue without resorting to a biopsy, the new study of 203 individuals was the first to show the method can identify various disease stages and risk factors, including a possible signature related to "family history."

The researchers' approach had a sensitivity of 95 percent for determining healthy tissue from cancerous tissue and appears to be the most successful yet developed for detecting pancreatic diseases at curable stages and for identifying high-risk individuals.

"These optical techniques have shown promise for detecting both colon and pancreatic cancer," says Backman. "Our hope is to continue to test the ability to detect other forms of cancer, which would greatly expand the impact of the technology." In ongoing work, the researchers will continue to refine their instrumentation and hope to validate the recent findings with further clinical trials.


'/>"/>

Contact: Joshua A. Chamot
jchamot@nsf.gov
703-292-7730
National Science Foundation
Source:Eurekalert

Related medicine news :

1. NEJM Report Finds HPV Test More Effective Than Pap in Determining Cervical Cancer Risk
2. CSHL scientists make progress in determining how the brain selectively interprets sound
3. New method proposed for determining which patients should get treatment for colorectal cancer
4. New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer
5. Determining genetic signature of lung tumors can help guide treatment
6. Fitness a Key Element in Determining Male Diabetics Longevity
7. PET/CT scan could be valuable noninvasive tool for determining stages of ovarian cancer
8. Past Earnings Play Role in Determining SSDI Benefits
9. Determining Valuations in Challenging Times
10. Gender is key factor in determining overall survival of lung cancer patients
11. Cancer stem cell subpopulation drives metastasis of human pancreatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... ... pharmaceutical inserts and outserts. As a means of expanding capabilities Flottman has ... enable Flottman to individually code professional inserts (PIs) and patient package inserts (PPIs) ...
(Date:12/9/2016)... York, NY (PRWEB) , ... December 09, 2016 , ... ... raises awareness for organ transplantation while encouraging readers to sign up as an organ ... a lifesaving organ transplant. , An organ donor can save up to 8 ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... will become Quality Insights beginning January 1, 2017. The name change aligns ... commitment to measuring and improving health care quality. , “We are very proud ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The ... ultimate weight loss and wellness program, at their world headquarters of Omni La Costa ... and long-term results to anyone seeking weight loss, personal development, a healthy lifestyle, or ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... LLC announced today that Steven E. Dawson has been appointed as chief ... Photo - http://photos.prnewswire.com/prnh/20161209/447552 ... Harmar ... Mr. Dawson,s executive career includes leadership roles managing and executing transformation, ... brings to the company deep operational and leadership expertise, a strong financial ...
(Date:12/9/2016)... Research and Markets has announced the addition of the ... ... travel vaccines market to grow at a CAGR of 6.83% during ... and the growth prospects of the global travel vaccines market for ... generated from the sales of various vaccines administered to actively immunize ...
(Date:12/8/2016)... 8, 2016 IRIDEX Corporation (NASDAQ: IRIX ... shares of common stock, $0.01 par value (the "Offering" with ... offering.  The final terms of the Offering will depend on ... there can be no assurance as to whether or when ... use the net proceeds it will receive from this offering ...
Breaking Medicine Technology: